Literature DB >> 24518912

The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.

Clare J Reade1, Ruaidhrí M McVey1, Alicia A Tone1, Sarah J Finlayson2, Jessica N McAlpine2, Michael Fung-Kee-Fung3, Sarah E Ferguson1.   

Abstract

Research published over the past 10 years has suggested that most "ovarian cancer," and specifically the high-grade serous carcinoma (HGSC) subtype of ovarian cancer, actually originates in the fallopian tube. In this review, we examine the evidence supporting the tubal origin hypothesis for HGSC, and discuss the clinical implications of our improved understanding of the pathogenesis of ovarian cancer. We searched Medline R and Medline in-process and non-indexed citations from inception to December 15, 2012, to identify all English or French language articles discussing the origins of HGSC. Articles and findings were summarized descriptively. A step-wise transformation from normal epithelium to a lesion with the ability to invade and metastasize has been demonstrated within the fallopian tube. Intraepithelial or early invasive carcinoma of the fallopian tube is frequently identified in BRCA mutation carriers who undergo prophylactic risk-reducing salpingo-oophorectomy. In both BRCA mutation carriers and women from the general population, pre-invasive changes within the fimbriated end of the fallopian tube appear in association with early HGSC. Molecular and genetic studies, as well as in vitro and animal models, have also supported a tubal origin for HGSC. Whether the removal of fallopian tubes (salpingectomy) at the time of pelvic surgery for other reasons will lead to reductions in mortality from ovarian cancer is currently unknown, but it is an important area for future clinical research.

Entities:  

Keywords:  HGSC; high-grade serous carcinoma; ovarian cancer; salpingectomy; serous tubal intraepithelial carcinoma; tubal origin hypothesis

Mesh:

Year:  2014        PMID: 24518912     DOI: 10.1016/S1701-2163(15)30659-9

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  29 in total

1.  Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.

Authors:  Geetha Balsarkar
Journal:  J Obstet Gynaecol India       Date:  2017-05-11

2.  An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Authors:  Marie E Perrone; Nicholas P Reder; Sergay N Agoff; Rochelle L Garcia; Kathy J Agnew; Barbara M Norquist; Kathryn P Pennington; Elizabeth M Swisher; Mark R Kilgore
Journal:  Int J Gynecol Pathol       Date:  2020-05       Impact factor: 2.762

3.  Circ-EEF2 facilitated autophagy via interaction with mir-6881-3p and ANXA2 in EOC.

Authors:  Min Yong; Jianguo Hu; Hongtao Zhu; Xinwei Jiang; Xiaolin Gan; Lina Hu
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

4.  Reversal of tubo-ovarian atypical epithelial patterns after cessation of ovarian stimulation by letrozole.

Authors:  Ahmed A M Abdel-Hamid; Yaser Mesbah; Mona F M Soliman
Journal:  Int J Exp Pathol       Date:  2016-09-01       Impact factor: 1.925

5.  Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

Authors:  Satish K Ramraj; Sugantha P Elayapillai; Richard C Pelikan; Yan D Zhao; Zitha R Isingizwe; Amy L Kennedy; Stanley A Lightfoot; Doris M Benbrook
Journal:  Int J Cancer       Date:  2020-01-08       Impact factor: 7.396

6.  Palmar fasciitis with polyarthritis-associated ovarian cancer: Case report and literature review.

Authors:  Hiroyuki Kajikawa; Takuya Sobajima; Chinatsu Koiwai; Satoshi Ichigo; Hiroshi Takagi; Atsushi Imai
Journal:  Mol Clin Oncol       Date:  2017-11-24

7.  Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci.

Authors:  Simon G Coetzee; Howard C Shen; Dennis J Hazelett; Kate Lawrenson; Karoline Kuchenbaecker; Jonathan Tyrer; Suhn K Rhie; Keren Levanon; Alison Karst; Ronny Drapkin; Susan J Ramus; Fergus J Couch; Kenneth Offit; Georgia Chenevix-Trench; Alvaro N A Monteiro; Antonis Antoniou; Matthew Freedman; Gerhard A Coetzee; Paul D P Pharoah; Houtan Noushmehr; Simon A Gayther
Journal:  Hum Mol Genet       Date:  2015-03-24       Impact factor: 6.150

8.  Ovarian cancer survival by tumor dominance, a surrogate for site of origin.

Authors:  Anna Ivanova; Anneli Loo; Shelley Tworoger; Christopher P Crum; Isabel Fan; John R McLaughlin; Barry Rosen; Harvey Risch; Steven A Narod; Joanne Kotsopoulos
Journal:  Cancer Causes Control       Date:  2015-03-13       Impact factor: 2.506

Review 9.  Secondary and tertiary ovarian cancer recurrence: what is the best management?

Authors:  Simone Garzon; Antonio Simone Laganà; Jvan Casarin; Ricciarda Raffaelli; Antonella Cromi; Massimo Franchi; Fabio Barra; Ibrahim Alkatout; Simone Ferrero; Fabio Ghezzi
Journal:  Gland Surg       Date:  2020-08

10.  Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort.

Authors:  Jennifer Ose; Helena Schock; Anne Tjønneland; Louise Hansen; Kim Overvad; Laure Dossus; Françoise Clavel-Chapelon; Laura Baglietto; Heiner Boeing; Antonia Trichopolou; Vassiliki Benetou; Pagona Lagiou; Giovanna Masala; Giovanna Tagliabue; Rosario Tumino; Carlotta Sacerdote; Amalia Mattiello; H B As Bueno-de-Mesquita; Petra H M Peeters; N Charlotte Onland-Moret; Elisabete Weiderpass; Inger T Gram; Soledad Sánchez; Mireia Obon-Santacana; Maria-José Sànchez-Pérez; Nerea Larrañaga; José María Huerta Castaño; Eva Ardanaz; Jenny Brändstedt; Eva Lundin; Annika Idahl; Ruth C Travis; Kay-Tee Khaw; Sabina Rinaldi; Isabelle Romieu; Melissa A Merritt; Marc J Gunter; Elio Riboli; Rudolf Kaaks; Renée T Fortner
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-08       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.